Literature DB >> 25673199

A novel prognostic score for acute-on-chronic hepatitis B liver failure.

Zhao-Quan Yi1, Meng-Hou Lu1, Xu-Wen Xu1, Xiao-Yu Fu1, De-Ming Tan2.   

Abstract

Patients with acute-on-chronic hepatitis B liver failure (HBV-ACLF) show high morbidity and mortality. Independent prognostic predictors of short-term HBV-ACLF mortality include the Child-Turcotte-Pugh (CTP) score, the model for end-stage liver disease (MELD) score, other MELD-based indices and the dynamic changes in these indices. The aims of this study were to evaluate the existing prognostic scores in a large cohort of HBV-ACLF patients and create a new predictive model. We retrospectively reviewed 392 HBV-ACLF patients from December 2008 to November 2011 and evaluated their 3-month survival. The predictive accuracy of CTP, MELD and MELD-based indices and the dynamic changes in the MELD-related scores (Δ scoring systems) upon admission and after two weeks of treatment were compared using the area under the receiver operating characteristic (ROC) curve method. Life-threatening factors and a series of bio-clinical parameters were studied by univariate and multivariate analyses. Among the existing scores, MELD had the best predictive ability. However, our new regression model provided an area under the curve of 0.930 ± 0.0161 (95% CI: 0.869 to 0.943), which was significantly larger than that obtained with the MELD score at admission and after two weeks of treatment as well as with the dynamic changes of the MELD score (0.819, 0.921, and 0.826, respectively) (Z=3.542, P=0.0004). In a large cohort of patients retrospectively reviewed for this study, our prognostic model was superior to the MELD score and is, therefore, a promising predictor of short-term survival in patients with HBV-ACLF.

Entities:  

Mesh:

Year:  2015        PMID: 25673199     DOI: 10.1007/s11596-015-1394-5

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  18 in total

1.  Dynamic changes in MELD score not only predict survival on the waiting list but also overall survival after liver transplantation.

Authors:  Georg P Györi; Gerd R Silberhumer; Sonja Zehetmayer; Barbara Kern; Hubert Hetz; Thomas Soliman; Rudolf Steininger; Ferdinand Mühlbacher; Gabriela A Berlakovich
Journal:  Transpl Int       Date:  2012-07-09       Impact factor: 3.782

Review 2.  The clinical challenges of acute on chronic liver failure.

Authors:  Ivo W Graziadei
Journal:  Liver Int       Date:  2011-09       Impact factor: 5.828

3.  Model for end-stage liver disease and Child-Turcotte-Pugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients.

Authors:  Robert S Brown; K Shiva Kumar; Mark W Russo; Milan Kinkhabwala; Dianne L Rudow; Patricia Harren; Steven Lobritto; Jean C Emond
Journal:  Liver Transpl       Date:  2002-03       Impact factor: 5.799

4.  Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure.

Authors:  Yao-Li Cui; Fang Yan; Yue-Bin Wang; Xue-Qin Song; Li Liu; Xue-Zhong Lei; Ming-Hua Zheng; Hong Tang; Ping Feng
Journal:  Dig Dis Sci       Date:  2010-05-29       Impact factor: 3.199

5.  Comparison of four prognostic models and a new Logistic regression model to predict short-term prognosis of acute-on-chronic hepatitis B liver failure.

Authors:  Wei-Ping He; Jin-Hua Hu; Jun Zhao; Jing-Jing Tong; Jin-Biao Ding; Fang Lin; Hui-Fen Wang
Journal:  Chin Med J (Engl)       Date:  2012-07       Impact factor: 2.628

6.  Model for end-stage liver disease-sodium predicts prognosis in patients with chronic severe hepatitis B.

Authors:  Chang-jie Cai; Hu-an Chen; Min-qiang Lu; Gui-hua Chen
Journal:  Chin Med J (Engl)       Date:  2008-10-20       Impact factor: 2.628

7.  Characteristics of acute and sub-acute liver failure in China: nomination, classification and interval.

Authors:  Qing Liu; Zheng Liu; Tailing Wang; Qingguo Wang; Xiaohong Shi; Wenbin Dao
Journal:  J Gastroenterol Hepatol       Date:  2007-12       Impact factor: 4.029

8.  MELD score: utility and comparison with King's College criteria in non-acetaminophen acute liver failure.

Authors:  Om Parkash; Khalid Mumtaz; Saeed Hamid; Syed Hasnain Ali Shah; S M Wasim Jafri
Journal:  J Coll Physicians Surg Pak       Date:  2012-08       Impact factor: 0.711

9.  Prediction of the prognosis of patients with acute-on-chronic hepatitis B liver failure using the model for end-stage liver disease scoring system and a novel logistic regression model.

Authors:  Q-F Sun; J-G Ding; D-Z Xu; Y-P Chen; L Hong; Z-Y Ye; M-H Zheng; R-Q Fu; J-G Wu; Q-W Du; W Chen; X-F Wang; J-F Sheng
Journal:  J Viral Hepat       Date:  2009-04-29       Impact factor: 3.728

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  4 in total

Review 1.  Early warning and clinical outcome prediction of acute-on-chronic hepatitis B liver failure.

Authors:  En-Qiang Chen; Fan Zeng; Ling-Yun Zhou; Hong Tang
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 2.  Acute-on-chronic liver failure: Pathogenesis, prognostic factors and management.

Authors:  Sara Blasco-Algora; José Masegosa-Ataz; María Luisa Gutiérrez-García; Sonia Alonso-López; Conrado M Fernández-Rodríguez
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

3.  Role of systemic inflammation in cirrhosis: From pathogenesis to prognosis.

Authors:  Melisa Dirchwolf; Andrés Eduardo Ruf
Journal:  World J Hepatol       Date:  2015-08-08

4.  Association of mRNA expression level of IP-10 in peripheral blood mononuclear cells with HBV-associated acute-on-chronic liver failure and its prognosis.

Authors:  Xiao-Lin Wang; Xiu-Ji Chen; Hai-Hui Ye; Ling-Xiang Xing; Xiao-Ying Han; Zheng-Jiang Cheng; Shao-Jun Huang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-10-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.